Suppr超能文献

治疗性浓缩物中血管性血友病因子的标准化:血管性血友病因子浓缩物第一国际标准品(00/514)的校准

Standardisation of von Willebrand Factor in therapeutic concentrates: calibration of the 1st International Standard for von Willebrand Factor concentrate (00/514).

作者信息

Hubbard Anthony R, Sands Dawn, Chang Andrew C, Mazurier Claudine

机构信息

National Institute for Biological Standards and Control, Potters Bar, UK.

出版信息

Thromb Haemost. 2002 Sep;88(3):380-6.

Abstract

An international study involving 26 laboratories assayed two candidate von Willebrand Factor (VWF) concentrates (B and C) for VWF:Antigen (VWF:Ag), VWF:Ristocetin Cofactor (VWF:RCo) and VWF:Collagen binding (VWF:CB) relative to the 4th International Standard Factor VIII/VWF Plasma (4th IS Plasma) (97/586). Estimates of VWF:Ag showed good agreement between different methods, for both candidates, and the overall combined means were 11.01 IU/ml with inter-laboratory variability (GCV) of 10.9% for candidate B and 14.01 IU/ml (GCV 11.8%) for candidate C. Estimates of VWF:RCo showed no significant difference between methods for both candidates and gave overall means of 9.38 IU/ml (GCV 23.7%) for candidate B and 10.19 IU/ml (GCV 24.4%) for candidate C. Prior to the calibration of the candidates for VWF:CB it was necessary to calibrate the 4th IS Plasma relative to local frozen normal plasma pools; there was good agreement between different collagen reagents and an overall mean of 0.83 IU per ampoule (GCV 11.8%) was assigned. In contrast, estimates of VWF:CB in both candidates showed large differences between collagen reagents with inter-laboratory GCV's of 40%. Candidate B (00/514) was established as the 1st International Standard von Willebrand Factor Concentrate by the WHO Expert Committee on Biological Standardisation in November 2001 with assigned values for VWF:Ag (11.0 IU/ampoule) and VWF:RCo (9.4 IU/ampoule). Large inter-laboratory variability of estimates precluded the assignment of a value for VWF:CB.

摘要

一项涉及26个实验室的国际研究,针对两种候选血管性血友病因子(VWF)浓缩物(B和C),检测了血管性血友病因子抗原(VWF:Ag)、血管性血友病因子瑞斯托霉素辅因子(VWF:RCo)以及血管性血友病因子胶原结合活性(VWF:CB),并与第4国际标准VIII因子/VWF血浆(4th IS血浆)(97/586)进行比较。对于两种候选浓缩物,不同方法对VWF:Ag的估计显示出良好的一致性,候选B的总体合并均值为11.01 IU/ml,实验室间变异系数(GCV)为10.9%,候选C为14.01 IU/ml(GCV 11.8%)。对于两种候选浓缩物,不同方法对VWF:RCo的估计无显著差异,候选B的总体均值为9.38 IU/ml(GCV 23.7%),候选C为10.19 IU/ml(GCV 24.4%)。在对候选浓缩物进行VWF:CB校准之前,有必要相对于当地冷冻正常血浆库对第4国际标准血浆进行校准;不同胶原试剂之间具有良好的一致性,每安瓿的总体均值为0.83 IU(GCV 11.8%)。相比之下,两种候选浓缩物中VWF:CB的估计在不同胶原试剂之间显示出较大差异,实验室间GCV为40%。2001年11月,候选B(00/514)被世界卫生组织生物标准化专家委员会确立为第1国际标准血管性血友病因子浓缩物,其VWF:Ag(11.0 IU/安瓿)和VWF:RCo(9.4 IU/安瓿)被赋予指定值。估计值存在较大的实验室间变异性,因此无法为VWF:CB赋予一个值。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验